FindTrial
Sign In

Non invasive detection of pulmonary artery hypertension in patients with left heart disease

Identifying Pulmonary Hypertension Phenotype in Left Heart Disease Patients Undergoing Cardiac Surgery Using Echocardiographic Variables: A prospective observational study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067073
Enrollment
85
Registered
2024-05-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I059- Rheumatic mitral valve disease, unspecified

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Dr Arshdeep Singh
Lead Sponsor
Dr BanaShree Mandal
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Left heart surgeries

Exclusion criteria

Exclusion criteria: 1. Poor TTE window 2. Contraindication to TEE probe insertion

Design outcomes

Primary

MeasureTime frame
To identify the phenotype of pulmonary hypertension using echocardiography parameters in patients with left heart disease undergoing cardiac surgery.Timepoint: Echo will be done at baseline, before cardiopulmonary bypass, post cardiopulmonary bypass, in the ICU when inotropes are tapered and 3 months post surgery—

Secondary

MeasureTime frame
1. To assess the effects of the pulmonary hypertension phenotype on right ventricular function in patients with left heart disease undergoing cardiac surgery. 2. To find correlation among invasive and non -invasive methods in classifying the phenotypes. 3. Quantification of pulmonary hypertension in perioperative period of cardiac surgery using invasive and non-invasive echocardiographic parameters. (upto 90 days postoperative period) 4. To assess the effects of pulmonary hypertension phenotype on post operative outcome a. Duration of mechanical ventilation b. Vasoactive-inotropic support c. Duration of ICU stay d. Morbidity and Mortality upto 90 daysTimepoint: 90 days—

Countries

India

Contacts

Public ContactDr Arshdeep Singh

PGIMER Chandigarh

banashreemandal@yahoo.co.in8146266102

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026